{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T04:36:23Z","timestamp":1790138183605,"version":"4.0.1"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T00:00:00Z","timestamp":1770940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Surgery is the standard treatment for oral cancer but often causes functional and cosmetic problems, and reoperation is difficult. Radiotherapy (RT) is less effective, with reirradiation limited by normal tissue tolerance and salvage surgery after RT carrying high complication risks. Systemic therapy is used for local recurrence but yields poor outcomes, underscoring the need for better options. Boron neutron capture therapy (BNCT) is an established method that selectively delivers high tumor doses. This study evaluated BNCT efficacy and safety in unresectable oral cancers not amenable to definitive RT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included oral cancer patients treated with BNCT between June 2020 and June 2024 under the Japanese public health insurance system. Primary endpoints were best treatment response and incidence of adverse events (AEs), particularly severe oral mucositis (Grade \u2265 3 by Common Terminology Criteria for AEs version 5). Predictors of severe oral mucositis were also examined. Secondary endpoints included overall survival (OS), locoregional control (LRC), and progression free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 74 patients (follow-up period \u22653 months), the majority (73%) had recurrent cancer. The complete response rate was 50%. The major severe acute AE was severe oral mucositis (all Grade 3) in 26% of patients. The maximum oral mucosal dose and the number of dental metals were significant predictors of severe oral mucositis. The 2-year OS, LRC, and PFS rates were 49%, 52%, and 29%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggests that BNCT is an effective and safe treatment for unresectable oral cancers that cannot be definitively irradiated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1735487","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:15Z","timestamp":1770960135000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Clinical outcomes of boron neutron capture therapy for unresectable oral cancer: a retrospective analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuki","family":"Yoshino","sequence":"first","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Department of Radiation Oncology, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Department of Radiology, Kyoto Prefectural University of Medicine","place":["Kyoto, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Takeno","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Department of Radiation Oncology, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teruhito","family":"Aihara","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Department of Otorhinolaryngology \u2013 Head and Neck Surgery, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naonori","family":"Hu","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Institute for Integrated Radiation and Nuclear Science, Kyoto University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Sasaki","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Akita","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Kanai","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Nojiri","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Jinnin","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology \u2013 Head and Neck Surgery, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Terada","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology \u2013 Head and Neck Surgery, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Haginomori","sequence":"additional","affiliation":[{"name":"Department of Otorhinolaryngology \u2013 Head and Neck Surgery, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Nihei","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"Department of Radiation Oncology, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Ono","sequence":"additional","affiliation":[{"name":"Kansai BNCT Medical Center, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]},{"name":"BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University","place":["Osaka, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,13]]},"reference":[{"key":"B1","volume-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines","year":"2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12070-018-1304-9","article-title":"Factors affecting postoperative complications after reconstructive surgery in oral carcinoma patients: a prospective study of 100 patients, Indian J","volume":"71","author":"Jain","year":"2019","journal-title":"Otolaryngol Head Neck Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2024.1669","article-title":"A hospital-based study of survival in oral cancer patients of Tata Memorial Hospital, Mumbai","volume":"18","author":"Lokhande","year":"2024","journal-title":"Ecancermedicalscience"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1620\/tjem.223.17","article-title":"Surgical treatment is recommended for advanced oral squamous cell carcinoma, Tohoku J","volume":"223","author":"Ogawa","year":"2011","journal-title":"Exp Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.oraloncology.2019.08.017","article-title":"Organs at risk\u2019s tolerance and dose limits for head and neck cancer re-irradiation: a literature review","volume":"98","author":"Dionisi","year":"2019","journal-title":"Oral Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.oraloncology.2017.01.007","article-title":"Re-irradiation for recurrent and second primary cancers of the head and neck","volume":"67","author":"Velez","year":"2017","journal-title":"Oral Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.12.055","article-title":"Salvage re-irradiation for recurrent head and neck cancer, Int","volume":"68","author":"Lee","year":"2007","journal-title":"J Radiat Oncol Biol Phys"},{"key":"B8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3109\/00016489.2011.617779","article-title":"High complication risk of salvage surgery after chemoradiation failures","volume":"132","author":"Sewnaik","year":"2012","journal-title":"Acta Otolaryngol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-008-0787-x","article-title":"Surgical complications of salvage total laryngectomy following concurrent chemoradiotherapy, Int","volume":"13","author":"Furuta","year":"2008","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110278","article-title":"Re-irradiation versus systemic therapy for the management of local-regionally recurrent head and neck cancer, Radiother","volume":"196","author":"Chen","year":"2024","journal-title":"Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2307\/3579742","article-title":"The radiation biology of boron neutron capture therapy, Radiat","volume":"151","author":"Coderre","year":"1999","journal-title":"Res"},{"key":"B12","volume-title":"Advances in boron neutron capture therapy","year":"2023"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2010.09.057","article-title":"Boron neutron capture therapy in the treatment of locally recurred head-and-neck cancer: final analysis of a phase I\/II trial, Int","volume":"82","author":"Kankaanranta","year":"2012","journal-title":"J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ijrobp.2016.02.028","article-title":"Fractionated boron neutron capture therapy in locally recurrent head and neck cancer: a prospective phase I\/II trial, Int","volume":"95","author":"Wang","year":"2016","journal-title":"J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12602","article-title":"Boronophenylalanine, a boron delivery agent for boron neutron capture therapy, is transported by ATB^{0,+}, LAT1 and LAT2","volume":"106","author":"Wongthai","year":"2015","journal-title":"Cancer Sci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v9.i1.21","article-title":"Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment, World J","volume":"9","author":"Hayashi","year":"2017","journal-title":"Gastrointest Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2020.11.001","article-title":"Boron neutron capture therapy using cyclotron-based epithermal neutron source and borofalan (10B) for recurrent or locally advanced head and neck cancer (JHN002): an open-label phase II trial, Radiother","volume":"155","author":"Hirose","year":"2021","journal-title":"Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2019.04.033","article-title":"Boron neutron capture therapy for locally recurrent head and neck squamous cell carcinoma: An analysis of dose response and survival","volume":"137","author":"Koivunoro","year":"2019","journal-title":"Radiother Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e7250","DOI":"10.1002\/cam4.7250","article-title":"Preliminary outcomes of boron neutron capture therapy for head and neck cancers as a treatment covered by public health insurance system in Japan: real-world experiences over a 2-year period","volume":"13","author":"Takeno","year":"2024","journal-title":"Cancer Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.ijrobp.2024.03.041","article-title":"Clinical results and prognostic factors in boron neutron capture therapy for recurrent squamous cell carcinoma of the head and neck under the Japan National Health Insurance System: a retrospective study of the initial 47 patients, Int","volume":"120","author":"Hirose","year":"2024","journal-title":"J Radiat Oncol Biol Phys"},{"key":"B21","article-title":"BNCT for head and neck cancer; current and future (in Japanese)","volume":"34","author":"Aihara","year":"2019","journal-title":"Bio Clin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.apradiso.2021.109747","article-title":"Neutron activation survey on patients following BNCT clinical trials at THOR, Appl","volume":"174","author":"Huang","year":"2021","journal-title":"Radiat Isot"},{"key":"B23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s13014-021-01968-2","article-title":"Evaluation of a treatment planning system developed for clinical boron neutron capture therapy and validation against an independent Monte Carlo dose calculation system, Radiat","volume":"16","author":"Hu","year":"2021","journal-title":"Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bj.2021.12.005","article-title":"Outcomes of re-irradiation for oral cavity squamous cell carcinoma, Biomed","volume":"45","author":"Chen","year":"2022","journal-title":"J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1038\/s41598-023-29459-2","article-title":"Reirradiation for local recurrence of oral, pharyngeal, and laryngeal cancers: a multi-institutional study, Sci","volume":"13","author":"Yamazaki","year":"2023","journal-title":"Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2011.02.023","article-title":"Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy, Int","volume":"81","author":"Sher","year":"2011","journal-title":"J Radiat Oncol Biol Phys"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2015.04.007","article-title":"D.G. Pfister (dup.), Definitive chemoradiation for primary oral cavity carcinoma: a single institution experience","volume":"51","author":"Scher","year":"2015","journal-title":"Oral Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1120\/jacmp.v16i3.5374","article-title":"Evaluation of the scatter doses in the direction of the buccal mucosa from dental metals","volume":"16","author":"Shimamoto","year":"2015","journal-title":"J Appl Clin Med Phys"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1186\/s12967-025-07349-7","article-title":"Tumor marker\u2013guided precision BNCT for CA19-9\u2013positive cancers: a new paradigm in molecularly targeted chemoradiation therapy","volume":"23","author":"Kanehira","year":"2025","journal-title":"J Transl Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejmp.2021.12.011","article-title":"Multimodal evaluation of 19F-BPA internalization in pancreatic cancer cells for boron capture and proton therapy potential applications","volume":"94","author":"Ciardiello","year":"2022","journal-title":"Phys Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2008.06.1493","article-title":"L-DOPA preloading increases the uptake of borophenylalanine in C6 glioma rat model: a new strategy to improve BNCT efficacy","volume":"72","author":"Capuani","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1735487\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T05:22:16Z","timestamp":1770960136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1735487\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,13]]},"references-count":31,"alternative-id":["10.3389\/fonc.2026.1735487"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1735487","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,13]]},"article-number":"1735487"}}